Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα
The study demonstrated that Pac inhibited the MAPKs signaling pathway and reduced hepatic ferroptosis, alleviated steatosis through PPARα regulation, offering a potential therapeutic strategy for MASLD.
Authors
- Guilin Ren (ORCID: https://orcid.org/0000-0002-6744-9713)
- Xiaobing Dou (ORCID: https://orcid.org/0000-0002-2465-3079)
- Xiaohui Fan (ORCID: https://orcid.org/0000-0002-6336-3007)
- Jiannan Qiu (ORCID: https://orcid.org/0000-0002-6736-7224)
- Lin Chen (ORCID: https://orcid.org/0000-0001-5363-9981)
- Linwensi Zhu (ORCID: https://orcid.org/0000-0001-7498-3765)
- Qingsheng Liu (ORCID: https://orcid.org/0000-0003-2721-4618)
- Yiyou Lin
Institutions
- Zhejiang Chinese Medical University (CN)
- Third People's Hospital of Hangzhou (CN)
- Hangzhou Hospital of Traditional Chinese Medicine (CN)
- Zhejiang Medicine (China) (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-06
- DOI
- https://doi.org/10.3389/fphar.2025.1554850
- Citations
- 6
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 9.11
Funders
- Zhejiang Chinese Medical University
- Natural Science Foundation of Zhejiang Province